BACK (IMAC Holdings) Moat Score: 2/10 (As of Jun. 26, 2026)


What is IMAC Holdings Moat Score?

IMAC Holdings BACK Moat Score is 2 as of Jun. 26, 2026. The stock has 7 warning signs investors should review. Among 681 Healthcare Providers & Services companies, IMAC Holdings ranks better than 79.3% on this metric.

IMAC Holdings has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

IMAC Holdings has No Moat: IMAC Holdings operates in a competitive healthcare sector with limited brand strength and customer loyalty. The company lacks significant intellectual property, cost advantages, or regulatory barriers, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes IMAC Holdings might have No Moat - Very weak/transient advantages.

IMAC Holdings  (OTCPK:BACK) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

IMAC Holdings Moat Score Related Terms

BACK vs FCHS, NHLG, NIVF: Moat Score Comparison

For the Medical Care Facilities subindustry, IMAC Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IMAC Holdings Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, IMAC Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where IMAC Holdings's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
IMAC Holdings (BACK) has a Moat Score of 2 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, IMAC Holdings ranks #141 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 20.7%.
Is IMAC Holdings' Moat Score too high?
IMAC Holdings' current Moat Score is 2. Based on the distribution chart, IMAC Holdings ranks #141 out of 681 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does IMAC Holdings' Moat Score compare to FCHS and NHLG?
According to the Healthcare Providers & Services industry distribution chart, IMAC Holdings ranks #141 out of 681 companies for Moat Score. This places IMAC Holdings in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. IMAC Holdings's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMAC Holdings stock overvalued right now?
IMAC Holdings (BACK) has a current Moat Score of 2. The current Moat Score is 2. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For IMAC Holdings (BACK), the current Moat Score is 2 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMAC Holdings Business Description

Address 3401 Mallory Lane, Suite 100, Franklin, TN, USA, 37067
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.